CAIX-targeted PET/CT in Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the diagnostic value of CAIX-targeted PET/CT imaging in various solid tumors, as well as the correlation between tumor uptake and tissue CAIX expression.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podejrzenie nowotworu złośliwego lub potwierdzony nowo wykryty/nawracający nowotwór litego
- •Wiek 18 lat i powyżej
- •Ogólny stan zdrowia oceniony na 0-1 punkt w skali ECOG
- •Dobrowolna zgoda na udział w badaniu
✗ Disqualifies
- •Poważne problemy z wątrobą, nerkami lub sercem
- •Znaczna otyłość lub klaustrofobia uniemożliwiająca badanie PET
- •Ciąża lub karmienie piersią
- •Inne stany zdrowia, które lekarz uzna za przeszkodę w udziale
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Zhongnan hospital of Wuhan University
Wuhan, China
Trial contact
Chongjiao Li, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.